MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...
Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback